[1]赵志廉,陆玲玲,郭 曼,等.育龄期女性乳腺癌中TIPE2的表达与VEGF、增殖能力的相关性分析[J].医学信息,2021,34(21):12-16.[doi:10.3969/j.issn.1006-1959.2021.21.003]
　ZHAO Zhi-lian,LU Ling-ling,GUO Man,et al.Correlation Analysis of TIPE2 Expression with VEGF and Proliferation Ability in Women of Childbearing Age Breast Cancer[J].Medical Information,2021,34(21):12-16.[doi:10.3969/j.issn.1006-1959.2021.21.003]
点击复制

育龄期女性乳腺癌中TIPE2的表达与VEGF、增殖能力的相关性分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年21期
页码:
12-16
栏目:
出版日期:
2021-11-01

文章信息/Info

Title:
Correlation Analysis of TIPE2 Expression with VEGF and Proliferation Ability in Women of Childbearing Age Breast Cancer
文章编号:
1006-1959（2021）21-0012-05
作者:
赵志廉; 陆玲玲; 郭 曼; 等
（昌邑市妇幼保健院病理科1，妇产科2，超声科3，外科4，山东 昌邑 261300）
Author(s):
ZHAO Zhi-lian; LU Ling-ling; GUO Man; et al.
(Department of Pathology1,Department of Obstetrics and Gynecology2,Department of Ultrasound3,Department of Surgery4,Changyi Maternal and Child Health Hospital,Changyi 261300,Shandong,China)
关键词:
乳腺癌; TIPE2; VEGF; β-catenin; cyclinD1; 增殖; Wnt
Keywords:
Breast cancer; TIPE2; VEGF; β-catenin; cyclinD1; Proliferation; Wnt
分类号:
R737.9
DOI:
10.3969/j.issn.1006-1959.2021.21.003
文献标志码:
A
摘要:
目的 探讨育龄期女性乳腺癌组织中的TIPE2的表达情况及与VEGF和增殖能力的相关性。方法 选取昌邑市妇幼保健院病理科2012年1月-2017年8月术前未行任何治疗的乳腺浸润性导管癌标本100份，采用免疫组织化学SP法先烤片，经过二甲苯、无水乙醇、梯度酒精、蒸馏水进行脱蜡水化，柠檬酸修复，滴加一抗、二抗，显色，染色；比较不同年龄、TNM分期、浸润程度、肿块大小、Ki-67、ER、PR、Her-2阳性表达患者的TIPE2、VEGF、β-catenin和cyclinD1表达情况，分析乳腺癌组织中TIPE2的表达与VEGF、β-catenin、cyclinD1的相关性。结果 TIPE2在乳腺癌组织中呈低表达，低于正常乳腺组织；VEGF、β-catenin、cyclinD1在乳腺癌组织中呈高表达，高于正常乳腺组织，差异均有统计学意义（P＜0.05）；单因素分析显示，TIPE2、VEGF、β-catenin、cyclinD1的表达与乳腺癌组织学级别、淋巴结转移、TNM分期、Ki67表达有关（P＜0.05），与肿瘤大小、年龄、ER、PR、HER-2的表达无关（P＞0.05）；相关性分析显示，TIPE2的表达与VEGF、β-catenin、cyclinD1的表达呈负相关（P＜0.05）；VEGF的表达与β-catenin、cyclinD1的表达呈正相关（P＜0.05）；β-catenin的表达与cyclinD1的表达呈正相关（P＜0.05）。结论 TIPE2、VEGF、β-catenin、cyclinD1与乳腺癌的增殖指数高恶性行为相关。TIPE2作用于乳腺癌的发生发展，在乳腺癌的发生发展机制可能与VEGF和Wnt通路相关。
Abstract:
Objective To investigate the expression of TIPE2 in breast cancer tissues of childbearing age women and its correlation with VEGF and proliferation ability.Methods A total of 100 specimens of breast invasive ductal carcinoma without any treatment before operation in the Department of Pathology, Changyi Maternal and Child Health Hospital from January 2012 to August 2017 were selected. The slices were roasted by immunohistochemical SP method, dewaxed and hydrated by xylene, anhydrous ethanol, gradient alcohol and distilled water, repaired by citric acid, and added with primary antibody and secondary antibody. The expression of TIPE2, VEGF, β-catenin and cyclinD1 in patients with different age, TNM stage, infiltration degree, tumor size, Ki-67, ER, PR and Her-2 positive expression were compared, and the correlation between TIPE2 expression and VEGF, β-catenin and cyclinD1 in breast cancer tissues was analyzed.Results The expression of TIPE2 in breast cancer tissues was lower than that in normal breast tissues. VEGF, β-catenin and cyclinD1 were highly expressed in breast cancer tissues, which were significantly higher than those in normal breast tissues (P<0.05). Univariate analysis showed that the expressions of TIPE2, VEGF, β-catenin and cyclinD1 were related to the histological grade, lymph node metastasis, TNM stage and Ki67 expression of breast cancer (P<0.05), was not correlated with tumor size, age, ER, PR and HER-2 (P>0.05). Correlation analysis showed that the expression of TIPE2 was negatively correlated with the expression of VEGF, β-catenin and cyclinD1 (P<0.05). The expression of VEGF was positively correlated with the expression of β-catenin and cyclinD1 (P<0.05). The expression of β-catenin was positively correlated with the expression of cyclinD1 (P<0.05).Conclusion TIPE2, VEGF, β-catenin and cyclinD1 are associated with high proliferation index and malignant behavior of breast cancer. TIPE2 acts on the occurrence and development of breast cancer, and its mechanism may be related to VEGF and Wnt pathways.

参考文献/References:

[1]Wormann B.Breast cancer: basics, screening, diagnostics and treatment[J].Med Monatsschr Pharm,2017,40(2):55-64. [2]Metelková A,Skálová A,Fínek J.Breast Cancer in Young Women - Correlation of Clinical Histomorphological, and Molecular-genetic Features of Breast Carcinoma in Women Younger than 35 Years of Age[J].Klin Onkol,2017,30(3):202-209.[3]Cordeiro CN,Gemignani ML.Breast Cancer in Pregnancy: Avoiding Fetal Harm When Maternal Treatment Is Necessary[J].Breast J,2017,23(2):200-205.[4]Liu R,He X,Geng W,et al.Loss of TIPE2 Has Opposing Effects on the Pathogenesis of Autoimmune Diseases[J].Front Immunol,2019(10):2284.[5]Zhang Z,Liu L,Cao S,et al.Gene delivery of TIPE2 inhibits breast cancer development and metastasis via CD8+ T and NK cell-mediated antitumor responses[J].Mol Immunol,2017(85):230-237.[6]Zhu L,Zhang X,Fu X,et al.TIPE2 suppresses progression and tumorigenesis of esophageal carcinoma via inhibition of the Wnt/β-catenin pathway[J].J Transl Med,2018,16(1):7.[7]Liu W,Fan Y,Shi Y,et al.Knockdown of TIPE2 increases the proliferation in lipopolysaccharide-stimulated gastric cancer cells[J].BMC Cancer,2018,18(1):857.[8]Wu DD,Liu SY,Gao YR,et al.Tumour necrosis factor-α-induced protein 8-like 2 is a novel regulator of proliferation, migration, and invasion in human rectal adenocarcinoma cells[J].J Cell Mol Med,2019,23(3):1698-1713.[9]Li T,Mello-Thoms C,Brennan PC.Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence[J].Breast Cancer Res Treat,2016,159(3):395-406. [10]Ji J,Zhang YY,Fan YC.TIPE2 as a potential therapeutic target in chronic viral hepatitis[J].Expert Opin Ther Targets,2019,23(6):485-493.[11]Li Z,Jia W,Niu J,et al.Understanding the roles of negative immune regulator TIPE2 in different diseases and tumourigenesis[J].Histol Histopathol,2018,33(9):919-928.[12]Wang Y,Lei L,Zheng YW,et al.Odd-skipped related 1 inhibits lung cancer proliferation and invasion by reducing Wnt signaling through the suppression of SOX9 and β-catenin[J].Cancer Sci,2018,109(6):1799-1810.[13]Lu Q,Liu Z,Li Z,et al.TIPE2 Overexpression Suppresses the Proliferation, Migration, and Invasion in Prostate Cancer Cells by Inhibiting PI3K/Akt Signaling Pathway[J].Oncol Res,2016,24(5):305-313.[14]Frezzetti D,Gallo M,Maiello MR,et al.VEGF as a potential target in lung cancer[J].Expert Opin Ther Targets,2017,21(10):959-966.[15]Costache MI,Ioana M,Iordache S,et al.VEGF Expression in Pancreatic Cancer and Other Malignancies: A Review of the Literature[J].Rom J Intern Med,2015,53(3):199-208.[16]Itatani Y,Kawada K,Yamamoto T,et al.Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway[J].Int J Mol Sci,2018,19(4):1232.[17]Suo LG,Cui YY,Bai Y,et al.Anti-inflammatory TIPE2 inhibits angiogenic VEGF in retinal pigment epithelium[J].Mol Immunol,2016(73):46-52.[18]Li Z,Guo C,Liu X,et al.TIPE2 suppresses angiogenesis and non-small cell lung cancer (NSCLC) invasiveness via inhibiting Rac1 activation and VEGF expression[J].Oncotarget,2016,7(38):62224-62239.[19]Sitt JC,Lui CY,Sinn LH,et al.Understanding breast cancer screening--past, present, and future[J].Hong Kong Med J,2018,24(2):166-174.[20]Li H, Zheng RS, Zhang SW,et al.Incidence and Mortality of Female Breast Cancer in China, 2014[J].Chinese Journal of Oncology,2018,40(3):166-171.

相似文献/References:

[1]董 云.SPECT/CT 双时相99mTc- MIBI断层显像 在乳腺癌诊断中的应用[J].医学信息,2018,31(05):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
　DONG Yun.Application of SPECT/CT Dual-phase 99mTc-MIBI Tomography in the Diagnosis of Breast Cancer[J].Medical Information,2018,31(21):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
[2]李建辉,祝旭龙.乳腺癌的治疗管理——把好生活质量关[J].医学信息,2018,31(13):1.[doi:10.3969/j.issn.1006-1959.2018.13.001]
[3]杨玉峰,李 强,曲国红,等.乳腺癌术前巴德枪穿刺检测ER、PR的临床研究[J].医学信息,2018,31(13):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
　YANG Yu-feng,LI Qiang,QU Guo-hong,et al.Clinical Study on Preoperative ER and PR Detection of Bard Gun Puncture in Breast Cancer[J].Medical Information,2018,31(21):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
[4]刘 曼,厉玛倩倩,徐润润,等.延续性护理对乳腺癌术后化疗患者生活质量与 健康知识水平的影响[J].医学信息,2018,31(16):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
　LIU Man,LIMA Qian-qian,XU Run-run,et al.Effect of Continuous Nursing on Quality of Life and Health Knowledge of Postoperative Chemotherapy Patients with Breast Cancer[J].Medical Information,2018,31(21):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
[5]张艳萍,曹 玉,孙国平.服用阿司匹林对乳腺癌患者生存获益的Meta分析[J].医学信息,2018,31(20):72.[doi:10.3969/j.issn.1006-1959.2018.20.021]
　ZHANG Yan-ping,CAO Yu,SUN Guo-ping.Meta Analysis of the Survival Benefit of Patients with Breast Cancer Treated with Aspirin[J].Medical Information,2018,31(21):72.[doi:10.3969/j.issn.1006-1959.2018.20.021]
[6]钟 磊,谢海燕,林 霖.电化学发光免疫分析技术检测肿瘤标志物在乳腺癌诊断中的应用[J].医学信息,2018,31(20):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
　ZHONG Lei,XIE Hai-yan,LIN Lin.Application of Electrochemiluminescence Immunoassay for Detection of Tumor Markers in Diagnosis of Breast Cancer[J].Medical Information,2018,31(21):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
[7]胡平华,黄 勤,李志华.含卡培他滨方案一线或后线治疗晚期乳腺癌的效果对比[J].医学信息,2018,31(22):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
　HU Ping-hua,HUANG Qin,LI Zhi-hua.Comparison of the Efficacy of Capecitabine Regimen in the Treatment of Advanced Breast Cancer with First-line or Posterior Line Therapy[J].Medical Information,2018,31(21):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
[8]阙海涛,曹 斌,秦志刚.EGFL7在乳腺癌中的研究进展[J].医学信息,2018,31(23):32.[doi:10.3969/j.issn.1006-1959.2018.23.010]
　QUE Hai-tao,CAO Bin,QIN Zhi-gang.Research Progress of EGFL7 in Breast Cancer[J].Medical Information,2018,31(21):32.[doi:10.3969/j.issn.1006-1959.2018.23.010]
[9]张文婧,宋 冰.HER-2阳性乳腺癌分子靶向治疗进展[J].医学信息,2018,31(24):42.[doi:10.3969/j.issn.1006-1959.2018.24.012]
　ZHANG Wen-jing,SONG Bing.Progress in Molecular Targeted Therapy for HER-2 Positive Breast Cancer[J].Medical Information,2018,31(21):42.[doi:10.3969/j.issn.1006-1959.2018.24.012]
[10]张 乐,徐胜昔,郭翔取,等.Tyrer-Cuzick模型联合SNPs位点在江西地区乳腺癌诊断中应用研究[J].医学信息,2018,31(24):131.[doi:10.3969/j.issn.1006-1959.2018.24.038]
　ZHANG Le,XU Sheng-xi,GUO Xiang-qu,et al.Application of Tyrer-Cuzick Model Combined with SNPs Locus in the Diagnosis of Breast Cancer in Jiangxi Area[J].Medical Information,2018,31(21):131.[doi:10.3969/j.issn.1006-1959.2018.24.038]

更新日期/Last Update: 1900-01-01